<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lipid abnormalities in nephrotic syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lipid abnormalities in nephrotic syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lipid abnormalities in nephrotic syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alessia Fornoni, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jai Radhakrishnan, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brad H Rovin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormal lipid metabolism is common in patients with kidney disease. This effect is most prominent in the nephrotic syndrome, where marked elevations in serum cholesterol and triglycerides often occur.
        </p>
        <p>
         This topic will review the pathogenesis and management of lipid abnormalities in patients with the nephrotic syndrome. The pathogenesis and management of lipid abnormalities in patients with chronic kidney disease and following kidney transplantation are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">
          "Lipid management in patients with nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">
          "Lipid abnormalities after kidney transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H283311178">
         <span class="h1">
          COMMON LIPID ABNORMALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with the nephrotic syndrome frequently have marked elevations in the plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipoprotein(a) [
         <a href="#rid1">
          1,2
         </a>
         ]. Total high-density lipoprotein cholesterol (HDL-C) levels are usually normal or reduced in the nephrotic syndrome, and there is often a pronounced decline in the cardioprotective HDL2 fraction. The following studies illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 207 adults with nephrotic syndrome due to nondiabetic kidney disease (mean proteinuria 7.2 g/24 hours), the mean total cholesterol concentration was 302 mg/dL (7.8 mmol/L), the mean LDL-C concentration was 208 mg/dL (5.4 mmol/L), and the mean triglyceride concentration was 251 mg/dL (2.8 mmol/L) [
         <a href="#rid3">
          3
         </a>
         ]. The mean HDL-C concentration was 44 mg/dL (1.1 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study of 100 patients with the nephrotic syndrome found that the plasma total cholesterol concentration exceeded 200 mg/dL (5.2 mmol/L) in 87 percent, 300 mg/dL (7.8 mmol/L) in 53 percent, and 400 mg/dL (10.3 mmol/L) in 25 percent [
         <a href="#rid4">
          4
         </a>
         ]. Approximately 77 percent of patients had an LDL-C level &gt;130 mg/dL (3.4 mmol/L), and 65 percent had an LDL-C level &gt;160 mg/dL (4.1 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 57 adults with the nephrotic syndrome, normal kidney function, and no other complicating diseases (such as diabetes), the mean serum triglyceride level was 230 mg/dL (2.6 mmol/L) among males and 223 mg/dL (2.5 mmol/L) among females [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some patients with the nephrotic syndrome may have no lipid abnormalities. As an example, normal serum cholesterol levels in the setting of overt nephrotic syndrome have been reported among nephrotic patients with renal amyloidosis and lupus nephritis [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         The concentration of plasma apolipoproteins in the nephrotic syndrome generally reflects the alterations in lipoprotein metabolism. Thus, there are elevated levels of apolipoprotein B (ApoB), ApoC-II, and ApoE, which are associated with very-low-density lipoprotein cholesterol (VLDL-C) and LDL-C; on the other hand, the levels of the major lipoproteins associated with HDL-C, ApoA-I and -A-II, are usually normal [
         <a href="#rid5">
          5
         </a>
         ]. A strong reduction in glomerular as well as plasma apolipoprotein M (ApoM) levels has been found in patients with glomerular diseases, and plasma ApoM level has been shown to be a predictor of complete remission [
         <a href="#rid8">
          8
         </a>
         ]. A review of the functions of the different apolipoproteins is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H530540443">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H1245611389">
         <span class="h2">
          LDL-C and cholesterol metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with the nephrotic syndrome frequently have marked elevations in serum total cholesterol and low-density lipoprotein cholesterol (LDL-C). This is due to a combination of increased biosynthesis and impaired catabolism of lipoproteins containing apolipoprotein B (ApoB) and cholesterol [
         <a href="#rid5">
          5,9-12
         </a>
         ]. Several mechanisms have been shown to contribute to these defects in cholesterol metabolism in patients and experimental animals with the nephrotic syndrome, including the following (
         <a class="graphic graphic_figure graphicRef130871" href="/z/d/graphic/130871.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity in the liver of nephrotic animals, resulting in increased cholesterol synthesis [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upregulation of the expression and activity of liver acetyl CoA acetyltransferase 2 (ACAT2), which results in enhanced esterification of cholesterol and a reduction in the level of intracellular free cholesterol [
         <a href="#rid10">
          10,15
         </a>
         ]. In experimental models of the nephrotic syndrome, pharmacologic inhibition of ACAT was shown to improve serum lipid levels and ameliorate proteinuria [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased hepatic lipase activity and decreased lipoprotein lipase (LPL) activity in the endothelium and peripheral tissues (such as muscle and adipose tissue), which results in impaired clearance of lipoproteins [
         <a href="#rid16">
          16-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased hepatic expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which promotes degradation of the low-density lipoprotein receptor (LDLR) and leads to acquired LDLR deficiency and, consequently, impaired LDL-C clearance [
         <a href="#rid22">
          22,23
         </a>
         ]. Increased PCSK9 expression in collecting duct cells has also been described in an experimental model of the nephrotic syndrome, and selective deficiency of collecting duct PCSK9 in this model was sufficient to prevent hypercholesterolemia associated with the nephrotic syndrome [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with the nephrotic syndrome have been shown to have elevated plasma PCSK9 levels that correlate with the degree of proteinuria and levels of total, non-high-density lipoprotein cholesterol (HDL-C), and LDL-C [
         <a href="#rid25">
          25,26
         </a>
         ]. In one series of nephrotic patients who went into remission, a decrease in plasma cholesterol was accompanied by a reduction in plasma PCSK9 [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition, plasma lipoprotein(a) levels are markedly elevated in patients with the nephrotic syndrome compared with healthy control patients [
         <a href="#rid3">
          3,28
         </a>
         ]. Both increased hepatic synthesis [
         <a href="#rid29">
          29
         </a>
         ] and decreased catabolism [
         <a href="#rid30">
          30
         </a>
         ] appear to be responsible.
        </p>
        <p class="headingAnchor" id="H1179394525">
         <span class="h2">
          HDL-C metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nephrotic syndrome results in significant alterations to the structure and function of high-density lipoprotein cholesterol (HDL-C). Patients with the nephrotic syndrome usually have normal to slightly reduced plasma HDL-C levels compared with healthy control patients [
         <a href="#rid31">
          31
         </a>
         ]; the HDL-C to total cholesterol ratio is generally decreased. The maturation of cholesterol ester-poor HDL3 to cholesterol ester-rich HDL2 is also impaired [
         <a href="#rid32">
          32,33
         </a>
         ], which results in impairment of HDL-C mediated reverse cholesterol transport. A number of mechanisms for these HDL-C abnormalities in the nephrotic syndrome have been proposed, including acquired lecithin-cholesterol acyltransferase (LCAT) deficiency, hypoalbuminemia, elevated levels of serum cholesterol ester transfer protein (CETP), and a reduction of hepatic HDL-C docking receptor SR-B1 [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Several experimental studies suggest that impaired reverse cholesterol transport in the kidney may contribute to proteinuria and disease progression in a number of glomerular disorders [
         <a href="#rid34">
          34,35
         </a>
         ]. Ongoing phase II trials will determine if newly developed reverse cholesterol transport inducers can improve nephrotic syndrome in patients with primary focal segmental glomerulosclerosis (FSGS; NCT05267262) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H652792798">
         <span class="h2">
          Triglyceride metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with the nephrotic syndrome frequently have elevated serum triglyceride, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein (IDL) levels. Impaired triglyceride metabolism, rather than enhanced synthesis, is primarily responsible for nephrotic hypertriglyceridemia (
         <a class="graphic graphic_figure graphicRef130871" href="/z/d/graphic/130871.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid9">
          9,37-39
         </a>
         ]. The delipidation cascade in which VLDL is converted to IDL and then to LDL-C by LPLs is slowed in the nephrotic syndrome [
         <a href="#rid38">
          38
         </a>
         ]. There is also a trend toward reduced LDLR-mediated clearance of LDL-C and IDL [
         <a href="#rid12">
          12,38
         </a>
         ]. How these changes occur is incompletely understood.
        </p>
        <p>
         The increase in IDL and VLDL levels in the nephrotic syndrome is primarily due to defective LPL activity and decreased hepatic lipase activity [
         <a href="#rid16">
          16
         </a>
         ]. Decreased LPL activity has been partly attributed to increased glomerular basement membrane permeability and the related loss of LPL activators [
         <a href="#rid40">
          40
         </a>
         ]. The concomitant downregulation of hepatic lipase in the nephrotic syndrome contributes to decreased clearance of IDL and hypertriglyceridemia. This may occur as a consequence of increased circulating angiopoietin-like 4 (ANGPTL4) in response to an elevated ratio of free fatty acids to albumin due to proteinuria [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Fatty acid uptake and accumulation of triglycerides in the kidney cortex have been shown to cause glomerular damage in experimental models of nephrotic syndrome [
         <a href="#rid42">
          42
         </a>
         ]. In addition, serum free fatty acid elevation may predict the development of acute kidney injury in nephrotic syndrome [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2992356521">
         <span class="h2">
          Other mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hyperlipidemic response is triggered at least in part by the reduction in plasma oncotic pressure, and the severity of the hyperlipidemia is inversely related to the fall in oncotic pressure [
         <a href="#rid5">
          5
         </a>
         ]. Spontaneous or drug-induced resolution of the nephrotic syndrome reverses the hyperlipidemia [
         <a href="#rid5">
          5,44
         </a>
         ]. (See
         <a class="local">
          'Treatment of nephrotic syndrome'
         </a>
         below.)
        </p>
        <p>
         A low oncotic pressure directly stimulates hepatic ApoB gene transcription [
         <a href="#rid45">
          45
         </a>
         ]. Furthermore, raising the plasma oncotic pressure with albumin or dextran reverses these changes in vitro [
         <a href="#rid45">
          45
         </a>
         ] and produces a rapid reduction in lipid levels in nephrotic patients [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         The reason why a low oncotic pressure stimulates lipoprotein production by the hepatocyte is not known [
         <a href="#rid45">
          45
         </a>
         ]. This is not a simple compensatory response, since lipoproteins are too large to significantly raise the oncotic pressure toward normal.
        </p>
        <p class="headingAnchor" id="H1685865092">
         <span class="h1">
          CLINICAL IMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a large body of literature implicating hypercholesterolemia as a major risk factor in the pathogenesis of atherosclerotic cardiovascular disease (CVD). Furthermore, lowering high cholesterol levels can decrease the incidence of coronary events by inducing regression and more importantly preventing progression of atherosclerotic lesions. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Studies to confirm these findings in patients with the nephrotic syndrome are largely lacking and unlikely to be performed. Nevertheless, it seems likely that patients with persistent nephrotic syndrome and hyperlipidemia are at increased risk for atherosclerotic CVD, particularly if other cardiovascular risk factors are present [
         <a href="#rid4">
          4,37,47
         </a>
         ]. In one study that compared 142 nondiabetic adult patients with nephrotic syndrome with matched controls, those with nephrotic syndrome had a higher risk of myocardial infarction (relative risk [RR] 5.5, 95% CI 1.6-18.3) and a nonsignificantly higher risk of coronary death (RR 2.8, 95% CI 0.7-11.3) [
         <a href="#rid47">
          47
         </a>
         ]. Rare cases of myocardial infarction occurring in children with nephrotic syndrome have also been reported [
         <a href="#rid48">
          48,49
         </a>
         ]. Thus, intensive lipid-lowering therapy to prevent CVD may be warranted in patients with chronic nephrotic syndrome who do not achieve disease remission.
        </p>
        <p>
         Experimental observations in animals with kidney disease and some observations in humans, particularly post-hoc analyses, suggest that hyperlipidemia may also enhance kidney injury due to direct effects on mesangial cells, podocytes, and tubular cells (the so-called "lipid nephrotoxicity hypothesis") [
         <a href="#rid2">
          2
         </a>
         ]. This may constitute an additional rationale for reducing lipid levels in nephrotic patients, although existing data suggest that statin therapy does not reduce the risk of kidney failure events among adults not receiving dialysis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H424163378">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no consensus guidelines on when or how to evaluate for hyperlipidemia in patients with the nephrotic syndrome. We obtain a fasting lipid panel (including total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein [HDL-C], and triglycerides) in all patients with the nephrotic syndrome at the time of diagnosis. If no lipid abnormalities are detected at the time of diagnosis, we repeat a fasting lipid panel every three months as long as the patient remains nephrotic.
        </p>
        <p>
         Given that nephrotic syndrome has been associated with an increased risk of atherosclerotic cardiovascular disease (CVD) (see
         <a class="local">
          'Clinical implications'
         </a>
         above), all patients with the nephrotic syndrome should undergo atherosclerotic CVD risk assessment similar to the general population. It is important to note that most commonly used CVD risk calculators have not been validated in patients under 40 years of age and do not include nephrotic syndrome as a potential factor in the estimation of risk. Thus, use of CVD risk calculators may not accurately assess CVD risk in patients with the nephrotic syndrome, particularly those who are younger or do not have preexisting CVD risk factors (such as hypertension or diabetes mellitus). The approach to CVD risk assessment in adults and children is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Our approach to ASCVD risk assessment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16975.html" rel="external">
          "Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children", section on 'Routine screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1164978207">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with the nephrotic syndrome, the management of hyperlipidemia focuses primarily on treatment of the nephrotic syndrome. Lifestyle modifications (including diet, increased physical activity, and weight reduction) and lipid-lowering therapy may be indicated for selected patients, such as those with persistent nephrotic syndrome and hyperlipidemia despite treatment of the underlying kidney disorder. However, evidence to guide the optimal therapy of hyperlipidemia in this patient population is limited.
        </p>
        <p class="headingAnchor" id="H767049911">
         <span class="h2">
          Treatment of nephrotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary approach to treating lipid abnormalities associated with the nephrotic syndrome is treatment of the underlying kidney disease responsible for causing the nephrotic syndrome. Such treatments may include immunosuppressive therapy as well as supportive measures, such as treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). The hyperlipidemia observed in the nephrotic syndrome generally reverses with resolution of the kidney disease. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         The reduction in protein excretion with ACE inhibitors or ARBs may be associated with a 10 to 20 percent decline in the plasma levels of total and low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [
         <a href="#rid51">
          51
         </a>
         ]. The magnitude of these changes appears to be related to the degree of fall in protein excretion, but they can occur with little or no elevation in the plasma albumin concentration.
        </p>
        <p class="headingAnchor" id="H2383196783">
         <span class="h2">
          Lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with hypercholesterolemia or hypertriglyceridemia associated with the nephrotic syndrome should be counseled on lifestyle modifications, such as a heart-healthy diet, increase in physical activity, smoking cessation, and weight reduction. Although these lifestyle modifications have not been well studied in patients with the nephrotic syndrome, these have been shown to have beneficial effects on preventing cardiovascular morbidity and mortality in the general population. Lifestyle changes are first-line treatment among children with dyslipidemia. (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease", section on 'Rationale'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">
          "Dyslipidemia in children and adolescents: Management", section on 'Heart-healthy lifestyle'
         </a>
         .)
        </p>
        <p>
         It is unclear whether dietary restriction of fats is beneficial to patients with hyperlipidemia associated with the nephrotic syndrome. In a randomized trial of 20 patients with chronic nephrotic syndrome published in 1993, the use of a vegetable soy diet that is low in fat and protein, cholesterol free, and rich in monounsaturated and polyunsaturated fatty acids produced a 25 to 30 percent reduction in lipid levels [
         <a href="#rid52">
          52
         </a>
         ]; however, these favorable effects may have been related to an accompanying reduction in proteinuria.
        </p>
        <p class="headingAnchor" id="H495929685">
         <span class="h2">
          Pharmacologic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3035762496">
         <span class="h3">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with the nephrotic syndrome should receive lipid-lowering therapies for primary or secondary prevention of cardiovascular disease (CVD) as appropriate based upon their assessed CVD risk (using a risk calculator) and estimated glomerular filtration rate (eGFR). Although the use of CVD risk calculators has not been specifically validated in patients with the nephrotic syndrome, we believe it is reasonable to extrapolate their use to most adults with the nephrotic syndrome. However, as previously noted (see
         <a class="local">
          'Evaluation'
         </a>
         above), such CVD risk calculators may not accurately assess CVD risk in younger patients with the nephrotic syndrome (age &lt;40 years) or those without preexisting CVD risk factors (such as hypertension or diabetes mellitus). (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">
          "Lipid management in patients with nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         In patients with the nephrotic syndrome who do
         <strong>
          not
         </strong>
         have an indication for primary or secondary CVD preventive therapies based upon their estimated CVD risk or eGFR, the optimal approach to pharmacologic lipid-lowering therapy is uncertain. There are no existing criteria for a threshold of hyperlipidemia at which pharmacologic therapy should be initiated and no data to guide the optimal timing or goals of pharmacologic therapy. Furthermore, there are no studies demonstrating that lowering lipid levels in patients with the nephrotic syndrome reduces the risk of CVD events. Thus, in the absence of clear evidence supporting its use, pharmacologic lipid-lowering therapy should be considered on a case-by-case basis after weighing the potential benefits and risks of treatment. Our approach, which is based primarily upon our clinical experience, is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We treat the cause of the nephrotic syndrome first since hyperlipidemia is expected to reverse with resolution of the nephrotic syndrome. (See
         <a class="local">
          'Treatment of nephrotic syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the nephrotic syndrome resolves within three to six months, we do not initiate pharmacologic lipid-lowering therapy unless indicated for primary or secondary CVD prevention based upon the patient's CVD risk and eGFR. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">
          "Lipid management in patients with nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the nephrotic syndrome does
         <strong>
          not
         </strong>
         resolve within three to six months (
         <a class="graphic graphic_algorithm graphicRef131648" href="/z/d/graphic/131648.html" rel="external">
          algorithm 1
         </a>
         ), we repeat a fasting lipid profile and initiate pharmacologic lipid-lowering therapy with a statin if the LDL-C is &gt;100 mg/dL (2.6 mmol/L) or if indicated for primary or secondary CVD prevention based upon the patient's estimated CVD risk (using a risk calculator) and eGFR. Choice and dosing of statin therapy are discussed below. In rare patients with an LDL-C ≤100 mg/dL (2.6 mmol/L) who have isolated severe hypertriglyceridemia (eg, serum triglycerides &gt;400 mg/dL), we treat with omega-3 fatty acids (such as
         <a class="drug drug_general" data-topicid="86044" href="/z/d/drug information/86044.html" rel="external">
          icosapent ethyl
         </a>
         , if available, or fish oil supplements) or a fibrate. (See
         <a class="local">
          'Statin therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">
          "Lipid management in patients with nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management", section on 'Marine omega-3 fatty acids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with persistent nephrotic syndrome, we use LDL-C in addition to estimated CVD risk (using a risk calculator) to guide decisions on lipid-lowering therapy since it is unclear that CVD risk can be accurately estimated with risk calculators in such patients (see
         <a class="local">
          'Evaluation'
         </a>
         above). However, there is no high-quality evidence to support the use of this (or any other) LDL-C threshold in patients with the nephrotic syndrome; this threshold is similar to that used for non-nephrotic patients without established CVD who are at very high risk for a CVD event.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our preference for waiting up to three to six months after initiation of treatment of the nephrotic syndrome is an arbitrary threshold, and some clinicians may choose to initiate pharmacologic therapy earlier or later in the course of treatment. We feel that it is reasonable to wait up to six months to start pharmacologic therapy since it is unclear that delaying therapy for up to this amount of time is associated with an increased long-term risk of CVD in this patient population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H55289053">
         <span class="h3">
          Statin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with persistent nephrotic syndrome who are initiated on pharmacologic lipid-lowering therapy (see
         <a class="local">
          'Our approach'
         </a>
         above), we suggest treatment with a statin rather than other therapies. Statins are the preferred first-line agents for treatment of hyperlipidemia in patients with the nephrotic syndrome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and efficacy
         </strong>
         – Several different formulations of statin therapy are available. The initial choice of agent is generally based upon potential drug interactions, price, side effects, and patient preference. We usually initiate treatment with a moderate-intensity statin (such as
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         10 to 20 mg daily or
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         20 to 40 mg daily). (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with hyperlipidemia associated with nephrotic syndrome, statins can lower the plasma total and LDL-C concentrations by 20 to 45 percent, with a lesser reduction in triglyceride levels [
         <a href="#rid37">
          37,53-56
         </a>
         ]. Lipoprotein(a) levels may also be reduced, especially in patients with high baseline values [
         <a href="#rid57">
          57
         </a>
         ]. However, there are limited data examining statins and CVD end points in nephrotic patients [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One report has suggested that statins may be renoprotective [
         <a href="#rid58">
          58
         </a>
         ], an effect possibly mediated by improvements in endothelial function [
         <a href="#rid59">
          59
         </a>
         ], but this finding has not been replicated in other larger studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring and goals of therapy
         </strong>
         – In patients receiving a statin, a fasting lipid profile should be monitored 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter to assess response and adherence to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal LDL-C target in patients with the nephrotic syndrome is not known. We titrate the statin dose to target an LDL-C goal of &lt;100 mg/dL (2.6 mmol/L) in view of the increased CVD risk in patients with the nephrotic syndrome. However, there is no evidence to support this (or any other) LDL-C target in patients with the nephrotic syndrome. If the target LDL-C cannot be achieved with maximally tolerated statin therapy, the use of additional second-line agents may be required. (See
         <a class="local">
          'Second-line agents and other therapies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – If the nephrotic syndrome eventually resolves with treatment, statin therapy can be discontinued unless lipid-lowering therapy is indicated for primary or secondary CVD prevention based upon the patient's CVD risk and eGFR. If the patient has persistent albuminuria or their eGFR is &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we continue therapy indefinitely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Statin side effects and intolerance, which vary somewhat among the statins, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Statins should be used with caution in patients who are concomitantly taking
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         . Coadministration of a statin with cyclosporine can increase statin levels and the risk of myotoxicity.
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         , which does not have a drug interaction with statins, can be used with statins without the need for dose adjustment [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events", section on 'Concurrent drug therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32236535">
         <span class="h3">
          Second-line agents and other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with persistent nephrotic syndrome who are treated with statin therapy may not be able to tolerate a statin or may not be able to achieve the target LDL-C despite treatment with a maximally tolerated statin. Others may have concomitant hypertriglyceridemia that is not responsive to statin therapy. For such patients, a number of second-line therapies are available, including
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         , proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, fibrates, bile acid sequestrants, nicotinic acid (
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          niacin
         </a>
         ), omega-3 fatty acids, and LDL apheresis. The efficacy of these second-line therapies is variable, and use of these agents is often limited by side effects [
         <a href="#rid37">
          37,53,61
         </a>
         ]. Our approach to second-line therapy, which is based upon
         <strong>
          low-quality
         </strong>
         evidence and our clinical experience, is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose LDL-C is ≥100 mg/dL (2.6 mmol/L) in spite of a maximally tolerated dose of a statin, we suggest adding
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         because of its safety profile and fewer adverse effects. If the target LDL-C still cannot be achieved with a statin plus ezetimibe, a PCSK9 inhibitor or a fibrate is a potential third-line agent. The cost, requirement for injections, and lack of long-term safety data with PCSK9 inhibitors may limit their use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are unable to tolerate statin therapy, we suggest either a PCSK9 inhibitor, a fibrate, or a bile acid sequestrant. As stated above, use of a PCSK9 inhibitor may be limited by its cost and requirement for injections. Bile acid sequestrants are considerably less expensive, but their use is frequently limited by their gastrointestinal side effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who have persistent and severe hypertriglyceridemia (eg, serum triglycerides &gt;400 mg/dL) in spite of a maximally tolerated dose of a statin, we suggest adding a fibrate.
        </p>
        <p>
        </p>
        <p>
         Evidence for second-line therapies is presented below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ezetimibe
         </strong>
         –
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          Ezetimibe
         </a>
         is the most commonly prescribed LDL-C-lowering agent after statins. It has limited vascular and clinical benefits but is frequently used in combination with statins or as an alternative agent in statin-intolerant patients. There are no available data evaluating the use of ezetimibe in patients with the nephrotic syndrome. In experimental models of nephrotic syndrome, ezetimibe was found to improve proteinuria and kidney triglyceride accumulation [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Ezetimibe'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PCSK9 inhibitors
         </strong>
         – PCSK9 inhibitors (eg,
         <a class="drug drug_general" data-topicid="103780" href="/z/d/drug information/103780.html" rel="external">
          evolocumab
         </a>
         and
         <a class="drug drug_general" data-topicid="103073" href="/z/d/drug information/103073.html" rel="external">
          alirocumab
         </a>
         ) may be beneficial for the treatment of hyperlipidemia in patients with nephrotic syndrome who cannot tolerate or are resistant to statin therapy. This potential benefit is based upon studies demonstrating that PCSK9 may be involved in the pathogenesis of nephrotic syndrome-associated hypercholesterolemia. (See
         <a class="local">
          'LDL-C and cholesterol metabolism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/106888.html" rel="external">
          "PCSK9 inhibitors: Pharmacology, adverse effects, and use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 12 patients with refractory nephrotic syndrome and uncontrolled hypercholesterolemia despite treatment with statins, treatment with a PCSK9 inhibitor decreased LDL-C levels by a mean of 37 percent after four weeks without significant changes in serum albumin levels or proteinuria [
         <a href="#rid62">
          62
         </a>
         ]. Plasma PCSK9 levels were reduced from a mean of 334 ng/mL at baseline to 190 ng/mL at six months after starting treatment (mean relative reduction of 42 percent). While these results are encouraging, additional studies are needed to confirm these findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrates
         </strong>
         – Fibrates, such as
         <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">
          gemfibrozil
         </a>
         , lower the total cholesterol level by 10 to 30 percent but are associated with an increased risk of myopathy, particularly if given with a statin. Fibrates have a more prominent effect on triglyceride metabolism, lowering the triglyceride concentration by as much as 50 percent. Data describing their efficacy in patients with nephrotic syndrome are limited [
         <a href="#rid56">
          56,63,64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Fibrates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bile acid sequestrants
         </strong>
         – Bile acid sequestrants (
         <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">
          colestipol
         </a>
         and
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          cholestyramine
         </a>
         ), in a dose of 15 to 25 grams per day, can lower the total cholesterol level by up to 30 percent when given alone [
         <a href="#rid61">
          61
         </a>
         ] and can produce an additive response when used with a statin [
         <a href="#rid54">
          54
         </a>
         ]. However, the gastrointestinal side effects of these drugs often limit patient adherence. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Bile acid sequestrants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nicotinic acid (
         </strong>
         <strong>
          niacin
         </strong>
         <strong>
          )
         </strong>
         – Nicotinic acid has only a modest hypolipidemic effect and is associated with a relatively high incidence of side effects such as flushing and headache. Intestinal symptoms have been reported in patients with chronic kidney disease [
         <a href="#rid65">
          65
         </a>
         ]. There are no available data evaluating the use of nicotinic acid in patients with the nephrotic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Nicotinic acid (niacin)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Omega-3 fatty acids
         </strong>
         – Supplementation of omega-3 fatty acids in patients with nephrotic syndrome or nephrotic-range proteinuria may reduce serum triglyceride levels, with mixed effects on LDL-C levels [
         <a href="#rid66">
          66,67
         </a>
         ]. While promising, these results need to be validated in larger studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LDL apheresis
         </strong>
         – LDL apheresis has been used in the treatment of drug-resistant hypercholesterolemia. (See
         <a class="medical medical_review" href="/z/d/html/4554.html" rel="external">
          "Treatment of drug-resistant hypercholesterolemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several uncontrolled studies have reported on the improvement of proteinuria and lipid parameters in adults and children with glucocorticoid-resistant nephrotic syndrome who were treated with LDL apheresis with or without glucocorticoids [
         <a href="#rid68">
          68-70
         </a>
         ]. Possible mechanisms underlying this effect include removal of toxic lipids, removal of autoantibodies and potential permeability factors, reduction of the vasoconstrictive prostanoid and thromboxane A2, and reduction of inflammatory cytokines [
         <a href="#rid70">
          70
         </a>
         ]. In the absence of randomized controlled trials, the role of this expensive therapy in treating nephrotic patients remains uncertain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H997159584">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Abnormal lipid metabolism is common in patients with kidney disease. This effect is most prominent in the nephrotic syndrome, where marked elevations in the plasma levels of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipoprotein(a) often occur. Patients with persistent nephrotic syndrome and hyperlipidemia are at increased risk for atherosclerotic cardiovascular disease (CVD), particularly if other cardiovascular risk factors are present. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Clinical implications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The hyperlipidemic response is triggered at least in part by the reduction in plasma oncotic pressure, which stimulates hepatic apolipoprotein B (ApoB) gene transcription. Diminished catabolism may also play a role. Impaired metabolism, rather than enhanced synthesis, is primarily responsible for nephrotic hypertriglyceridemia. Spontaneous or drug-induced resolution of the nephrotic syndrome reverses the hyperlipidemia. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – There are no consensus guidelines on when or how to evaluate for hyperlipidemia in patients with the nephrotic syndrome. We obtain a fasting lipid panel (including total cholesterol, LDL-C, high-density lipoprotein [HDL-C], and triglycerides) in all patients with the nephrotic syndrome at the time of diagnosis. All patients with the nephrotic syndrome should be evaluated for hyperlipidemia. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – In patients with the nephrotic syndrome, the management of hyperlipidemia focuses primarily on treatment of the nephrotic syndrome. Lifestyle modifications (including diet, increased physical activity, and weight reduction) and lipid-lowering therapy may be indicated for selected patients, such as those with persistent nephrotic syndrome and hyperlipidemia despite treatment of the underlying kidney disorder. However, evidence to guide the optimal therapy of hyperlipidemia in this patient population is limited. (See
         <a class="local">
          'Treatment of nephrotic syndrome'
         </a>
         above and
         <a class="local">
          'Lifestyle modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All patients with the nephrotic syndrome should receive lipid-lowering therapies for primary or secondary prevention of CVD as appropriate based upon their assessed CVD risk (using a risk calculator) and estimated glomerular filtration rate (eGFR). (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">
          "Lipid management in patients with nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with the nephrotic syndrome who do
         <strong>
          not
         </strong>
         have an indication for primary or secondary CVD preventive therapies based upon their estimated CVD risk or eGFR, the optimal approach to pharmacologic lipid-lowering therapy is uncertain. There are no existing criteria for a threshold of hyperlipidemia at which pharmacologic therapy should be initiated and no data to guide the optimal timing or goals of pharmacologic therapy. Our approach, which is based primarily upon our clinical experience, is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We treat the cause of the nephrotic syndrome first since hyperlipidemia is expected to reverse with resolution of the nephrotic syndrome. If the nephrotic syndrome resolves within three to six months, we do not initiate pharmacologic lipid-lowering therapy unless indicated for primary or secondary CVD prevention based upon the patient's CVD risk and eGFR. For patients whose nephrotic syndrome does
         <strong>
          not
         </strong>
         resolve within three to six months
         <strong>
          and
         </strong>
         who have an LDL-C &gt;100 mg/dL (2.6 mmol/L), we suggest initiating pharmacologic lipid-lowering therapy with a statin, rather than other pharmacologic therapies or no pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (
         <a class="graphic graphic_algorithm graphicRef131648" href="/z/d/graphic/131648.html" rel="external">
          algorithm 1
         </a>
         ). However, for patients who cannot tolerate a statin, a PCSK9 inhibitor, fibrate, or bile acid sequestrant can be used as an alternative. In rare patients with an LDL-C ≤100 mg/dL (2.6 mmol/L) who have isolated hypertriglyceridemia, we treat with omega-3 fatty acids (such as
         <a class="drug drug_general" data-topicid="86044" href="/z/d/drug information/86044.html" rel="external">
          icosapent ethyl
         </a>
         , if available, or fish oil supplements) or a fibrate. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="local">
          'Statin therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Some patients with persistent nephrotic syndrome who are treated with statin therapy may not be able to tolerate a statin or may not be able to achieve the target LDL-C despite treatment with a maximally tolerated statin. For patients whose LDL-C is ≥100 mg/dL (2.6 mmol/L) in spite of a maximally tolerated dose of a statin, we suggest adding
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If the target LDL-C still cannot be achieved with a statin plus ezetimibe, a PCSK9 inhibitor or fibrate is a potential third-line agent. For patients who have persistent and severe hypertriglyceridemia in spite of a maximally tolerated dose of a statin, we suggest adding a fibrate (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Second-line agents and other therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1065743">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Gerald B Appel, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016; 90:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018; 14:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004; 66:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993; 22:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joven J, Villabona C, Vilella E, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HEPTINSTALL RH, JOEKES AM. Renal amyloid. A report on eleven cases proven by renal biopsy. Ann Rheum Dis 1960; 19:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SHEARN MA. NORMOCHOLESTEROLEMIC NEPHROTIC SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS. Am J Med 1964; 36:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drexler Y, Molina J, Elfassy T, et al. Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease. Kidney Int Rep 2023; 8:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND, Liang KH. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome. Circulation 2004; 110:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demant T, Mathes C, Gütlich K, et al. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 1998; 54:2064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995; 47:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003; 63:1756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995; 48:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002; 61:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garber DW, Gottlieb BA, Marsh JB, Sparks CE. Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 1984; 74:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaysen GA, Mehendru L, Pan XM, Staprans I. Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 1992; 263:F335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy E, Ziv E, Bar-On H, Shafrir E. Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1990; 1043:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002; 61:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 1997; 130:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND, Yuan J, Ni Z, et al. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 2012; 16:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 2014; 29:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 2014; 63:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina-Jijon E, Gambut S, Macé C, et al. Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome. Kidney Int 2020; 98:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwakernaak AJ, Lambert G, Slagman MC, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 2013; 226:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doiron S, Paquette M, Baass A, et al. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study. Clin Biochem 2022; 109-110:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas ME, Levenson AE, Sun X, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation 2016; 134:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenvinkel P, Berglund L, Ericsson S, et al. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest 1997; 27:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaysen GA, Hoye E, Jones H Jr. Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol 1995; 268:F532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol 2016; 12:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gherardi E, Rota E, Calandra S, et al. Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 1977; 7:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muls E, Rosseneu M, Daneels R, et al. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 1985; 54:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedigo CE, Ducasa GM, Leclercq F, et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Invest 2016; 126:3336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducasa GM, Mitrofanova A, Mallela SK, et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J Clin Invest 2019; 129:3387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright MB, Varona Santos J, Kemmer C, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun 2021; 12:4662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warwick GL, Packard CJ, Demant T, et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991; 40:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shearer GC, Stevenson FT, Atkinson DN, et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001; 59:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clement LC, Macé C, Avila-Casado C, et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 2014; 20:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JJ, David JM, Wilbon SS, et al. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine 2021; 63:103162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Cui L, Li C, et al. Serum free fatty acid elevation is related to acute kidney injury in primary nephrotic syndrome. Ren Fail 2022; 44:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenvinkel P, Berglund L, Heimbürger O, et al. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993; 44:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi A, Fukuhara Y, Yamamoto S, et al. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992; 263:C397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BAXTER JH, GOODMAN HC, ALLEN JC. Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 1961; 40:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suryawanshi SP, Das B, Patnaik AN. Myocardial infarction in children: Two interesting cases. Ann Pediatr Cardiol 2011; 4:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva JM, Oliveira EA, Marino VS, et al. Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol 2002; 17:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su X, Zhang L, Lv J, et al. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 67:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keilani T, Schlueter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993; 118:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico G, Gentile MG, Manna G, et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992; 339:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabelink AJ, Hené RJ, Erkelens DW, et al. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988; 2:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong X, Yuan H, Fan J, et al. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev 2013; :CD005425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown CD, Azrolan N, Thomas L, et al. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am J Kidney Dis 1995; 26:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogra GK, Watts GF, Herrmann S, et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002; 62:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migliozzi DR, Asal NJ. Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions. Ann Pharmacother 2020; 54:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeri A, Gelfand J, Blum C, Appel GB. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 1986; 8:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jatem E, Lima J, Montoro B, et al. Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. Kidney Int Rep 2021; 6:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 1989; 36:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büyükçelik M, Anarat A, Bayazit AK, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002; 44:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ix JH, Isakova T, Larive B, et al. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 2019; 30:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell S, Cooney J, Packard CJ, et al. The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. Clin Nephrol 2012; 77:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall AV, Parbtani A, Clark WF, et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol 1992; 3:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muso E, Mune M, Fujii Y, et al. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl 1999; 71:S122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raina R, Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol 2019; 34:1655.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3114 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27165836" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29176657" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200443" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8322776" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The nephrotic syndrome, lipids, and risk factors for cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2381443" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14401190" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal amyloid. A report on eleven cases proven by renal biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14124691" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : NORMOCHOLESTEROLEMIC NEPHROTIC SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37069998" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2002630" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lipid abnormalities in renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262831" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9853272" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723244" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12675851" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8587261" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11967026" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6480830" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Catabolism of very low density lipoproteins in experimental nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1510125" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2322571" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786096" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9358077" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gene expression of lipoprotein lipase in experimental nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22009636" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24166456" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24315769" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32750454" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23261172" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35940295" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27358438" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8328733" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9061312" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900854" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26568191" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : HDL abnormalities in nephrotic syndrome and chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/415877" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3986019" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lipoprotein distribution and composition in the human nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27482889" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31329164" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34341345" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8128933" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1921148" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11135070" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6128601" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24317117" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33340991" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35912916" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Serum free fatty acid elevation is related to acute kidney injury in primary nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264144" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lipoprotein(a) in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1381147" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13688076" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8231039" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The increased risk of coronary heart disease associated with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21677815" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Myocardial infarction in children: Two interesting cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956853" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Premature acute myocardial infarction in a child with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26905361" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420442" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1349366" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564077" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lipid-lowering therapy in patients with renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2904053" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264145" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24327265" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Lipid-lowering agents for nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7611249" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612979" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110017" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Statin therapy improves brachial artery endothelial function in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31441337" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3544820" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426389" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2779095" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of nephrotic hyperlipoproteinemia with gemfibrozil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11858378" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31085679" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595386" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1477328" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10412754" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14655182" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30218191" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : An update on LDL apheresis for nephrotic syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
